3,4-亚甲二氧基-N-乙基安非他命 | 82801-81-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 中文名称: 3,4-亚甲二氧基-N-乙基安非他命
• 中文别名: 甲醇(N-甲基二乙醇胺)；N-乙基-1-(3,4-亚甲二氧基苯基)-2-丙胺
• 英文名称: 3,4-methylenedioxyethylamphetamine
• 英文别名: MDEA；3,4-methylenedioxyethamphetamine；3,4-methylenedioxy-N-ethylamphetamine；N-ethyl-3,4-methylenedioxyamphetamine；1-(1,3-benzodioxol-5-yl)-N-ethylpropan-2-amine
• CAS: 82801-81-8
• 化学式: C₁₂H₁₇NO₂
• 分子量: 207.272
• InChiKey: PVXVWWANJIWJOO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3,4-亚甲二氧基-N-乙基安非他命 在 human liver microsomes 还原型辅酶II(NADPH)四钠盐 作用下， 以 phosphate buffer 为溶剂， 反应 0.25h， 生成 替苯丙胺
  参考文献：
  名称：

  Identification of the human cytochromes P450 involved in the oxidative metabolism of “Ecstasy”-related designer drugs

  摘要：

  The human cytochrome P450 (CYP) isozymes catalyzing the oxidative metabolism of the widely abused amphetamine derivatives MDMA (N-methyl-3,4-mechylenedioxyamphetamine, "Ecstasy"), MDE (Nethyl-3,4-methylenedioxyampheramine, "Eve"), and MDA (3,4-mechylenedioxyamphetamine) were identified. Using a simplified non-extractive reversed-phase HPLC assay with fluorescence detection, biphasic Michaelis-Menten kinetics were obtained for formation of all three dihydroxyamphetamines in liver microsomes from a CYP2D6 extensive metabolizer subject. In contrast, no low K-m component was detectable in microsomes from a poor metabolizer subject. Additional specific probes for CYP2D6 further confirmed this isozyme as the exclusive low K-m component for demethylenation. P450-selective inhibitors applied to CYP2D6-inhibited microsomes and activity measurements in a series of recombinant P450s suggested CYP1A2 as the major high K-m component with contributions by CYP2B6 and CYP3A4. Moreover, the relative CYP1A2 content of a panel of 12 human livers was weakly but significantly correlated to the high K-m demethylenase activity (Spearman rank correlation coefficient [r(s)] = 0.58; P < 0.05). Microsomal maximal velocities for N-dealkylation were at least 7-fold lower than for demethylenation and were characterized by apparently monophasic kinetics. The most important isozyme for this reaction appeared to be CYP2B6, the microsomal content of which was found to be strongly correlated to N-deethylation of MDE (r(s) = 0.90; P < 0.001). We conclude that, in addition to CP2D6 as the sole high-affinity demethylenase, several other P450 isozymes have the capacity to contribute to microsomal oxidative metabolism of methylenedioxyamphetamines. This may be of particular importance in individuals genetically lacking functional CYP2D6. (C) 2000 Elsevier Science Inc.

  DOI：

  10.1016/s0006-2952(00)00284-7
• 作为产物：
  描述：

  替苯丙胺 在 吡啶 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 90.0h， 生成 3,4-亚甲二氧基-N-乙基安非他命
  参考文献：
  名称：

  3,4-亚甲基二氧基苯基异丙胺（3,4-亚甲基二氧基苯丙胺）的中枢活性N-取代类似物。

  摘要：

  3，4-亚甲基二氧基苯基异丙基胺及其N-甲基同系物的已知中枢神经系统活性促使合成一系列在氮原子上具有取代基的类似物。这些类似物的大多数（R =烷基，烯基，羟基，烷氧基和烷氧基烷基）是通过3,4-亚甲基二氧基苯基丙酮与适当的胺和氰基硼氢化钠进行还原性烷基化反应制备的。受阻异构体是间接合成的。在几种动物试验和人类受试者中对它们的药理活性的测量表明，中央活性随N取代基体积的增加而降低。

  DOI：

  10.1002/jps.2600690220

文献信息

• [EN] IMIDAZOLIUM REAGENT FOR MASS SPECTROMETRY<br/>[FR] RÉACTIF D'IMIDAZOLIUM POUR SPECTROMÉTRIE DE MASSE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2021234004A1

  公开（公告）日：2021-11-25

  The present invention relates to compounds which are suitable to be used in mass spectrometry as well as methods of mass spectrometric determination of analyte molecules using said compounds.

  本发明涉及适用于质谱的化合物，以及利用该化合物进行分析物分子的质谱测定方法。
• AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS
  申请人：CHEMAPOTHECA, LLC

  公开号：US20180243241A1

  公开（公告）日：2018-08-30

  The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

  这项发明还涉及包含高纯度苯丙胺和苯丙胺类化合物的药物组合物，这些化合物是通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成而得到的，并且涉及通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成而得到的苯丙胺化合物的制造、输送和使用方法。
• [EN] AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE DETERRENT DOSAGE FORMS<br/>[FR] LIBÉRATION CONTRÔLÉE DE L'AMPHÉTAMINE, PROMÉDICAMENT ET FORMES POSOLOGIQUES DISSUASIVES DU MÉSUSAGE
  申请人：CHEMAPOTHECA LLC

  公开号：WO2017147375A1

  公开（公告）日：2017-08-31

  The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

  这项发明还涉及包含高纯度苯丙胺和苯丙胺类化合物的药物组合物，这些化合物是通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成的，以及通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成的苯丙胺化合物的制造、输送和使用方法。
• [EN] ASSAY FOR ENTACTOGENS<br/>[FR] ESSAI D'ENTACTOGENES
  申请人：DADE BEHRING INC

  公开号：WO2005058864A1

  公开（公告）日：2005-06-30

  Methods, compositions and kits are disclosed. The methods are directed to determining the presence of entactogen analytes such as, for example, 3,4­methylenedioxyamphetamine (MDA)3,4-methylenedioxy-methamphetamine (MDMA), 3,4-methylenedioxy-ethylamphetamine (MDEA) and 4-hydroxy-3-methoxy­methamphetamine (HMMA). The method comprises providing in combination in a medium (i) a sample suspected of containing the compound and (ii) an antibody raised against a compound of Formula I that comprises a protein. The medium is examined for the presence a complex comprising the compound and the antibody where the presence of such as complex indicates the presence of the compound in the sample. In one aspect of the above embodiment, the combination further comprises a label conjugate of the compound Formula I.

  揭示了方法、组合物和试剂盒。这些方法旨在确定致幻药物分析物的存在，例如3,4-亚甲二氧苯丙胺（MDA）、3,4-亚甲二氧甲基苯丙胺（MDMA）、3,4-亚甲二氧乙基苯丙胺（MDEA）和4-羟基-3-甲氧基苯丙胺（HMMA）。该方法包括在介质中组合提供（i）疑似含有该化合物的样品和（ii）针对包含蛋白质的化合物的I式的抗体。检查介质是否存在包含该化合物和抗体的复合物，其中这种复合物的存在表明样品中存在该化合物。在上述实施例的一个方面，该组合进一步包括化合物I式的标记结合物。
• [EN] ECSTASY HAPTENS AND IMMUNOGENS<br/>[FR] HAPTENES ET MMUNOGENES CONTRE L'ECSTASY
  申请人：DADE BEHRING INC

  公开号：WO2005061482A1

  公开（公告）日：2005-07-07

  Methods, compositions and kits are disclosed. Enzyme conjugates of Formula (I) are employed in assays for the determination of an methylenedioxyamphetamine, a methylene-dioxyethamphetamine, and/or a methylenedioxymethamphetamine. Immunogenic conjugates of Formula I are employed to prepare antibodies for an methylenedioxyamphetamine, a methylenedioxyethamphetamine, and/or for a methylene- dioxymethamphetamine for use in assays for the determination of an methylenedioxyamphetamine, a methyl enedioxyethamphetamine, and/or a methylene-dioxymethamphetamine. The enzyme conjugates may also be employed to screen antibodies for use in such methods.

  方法、组合物和试剂盒已被披露。式（I）的酶结合物被用于测定甲基二氧苯丙胺、亚甲二氧乙胺和/或亚甲二氧甲基苯丙胺。式I的免疫原结合物被用于制备用于测定甲基二氧苯丙胺、亚甲二氧乙胺和/或亚甲二氧甲基苯丙胺的抗体，用于测定甲基二氧苯丙胺、亚甲二氧乙胺和/或亚甲二氧甲基苯丙胺的试剂盒。酶结合物也可用于筛选用于这些方法的抗体。